News
Resources
Blog
Sites
Nicole Longo Nicole is senior director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
New analysis adds to research questioning whether 340B is working as Congress intended
By Nicole Longo | October 13, 2021
As the 340B program has grown over the past decade, there has been increased interest in it and ensuring it works in the best interest of patients. Unfortunately, study after study finds that...
Read More
Five reasons tying VA prices to Medicare Part D misses the mark
By Nicole Longo | September 22, 2021
Some members of Congress are considering a government “negotiation” plan that would tie medicine prices in Medicare to those in the U.S. Department of Veterans Affairs (VA). This misguided...
Read More
340B hospitals among those that provide lowest levels of community benefit across the country
By Nicole Longo | July 27, 2021
The 340B program reached $38 billion in sales at the discounted price in 2020. This is a 27% increase over sales in 2019, and the program is now more than four times the size it was in 2014....
Read More
Cross-country comparisons of medicine prices are like comparing apples to oranges
By Nicole Longo | March 22, 2021
Looking at differences in medicine prices between the United States and other countries can be misleading, often ignoring the complexities in the U.S. system and the repercussions of other...
Read More
Getting the 340B program back on track in 2021
By Nicole Longo | March 10, 2021
As our nation continues to fight a global pandemic, the need for access to affordable and quality health care feels even more pressing. This is especially true for vulnerable patients who have...
Read More
American biopharmaceutical manufacturing: Fueling economic growth now and for years to come
By Nicole Longo | December 21, 2020
As the world has grappled with the current pandemic, there has been increased focus on biopharmaceutical manufacturing and its global supply chain. Many wondered whether the biopharmaceutical...
Read More
Correcting the record: Biopharmaceutical companies remain committed to the 340B program and helping patients
By Nicole Longo | December 17, 2020
The New York Times recently ran a story that paints an inaccurate picture of the 340B program, contract pharmacy participation in the program and the biopharmaceutical industry’s commitment to the...
Read More
Key takeaways from new GAO report on covered entities’ lack of compliance with 340B requirements
By Nicole Longo | December 15, 2020
In case you missed it, the Government Accountability Office (GAO) released a new report looking at the 340B program and the mechanisms the government has to help ensure compliance with the...
Read More
New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England
By Nicole Longo | December 10, 2020
In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to...
Read More
No matter how you look at it, the Most Favored Nation rule is bad policy
By Nicole Longo | December 1, 2020
Last month, the administration released the “Most Favored Nation” (MFN) rule, which allows foreign governments to decide the value of Part B medicines, while also likely limiting seniors’ access...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
